
Patient priorities and practice logistics should guide therapy selection in BCG-unresponsive NMIBC, according to Katie S. Murray, DO, MS, FACS.
FDA will hold a public workshop on prostate cancer as part of its ongoing series of meetings on oncology clinical trial endpoints.






